Gilead’s $21 billion gamble is a dramatic shot to secure a promising first-in-class oncology drug.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Signaling pathways and therapeutic interventions in gastric cancer
Signal Transduction and Targeted Therapy Open Access 08 October 2022
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shaffer, C. Trop2 deal heats up antibody–drug conjugate space in cancer. Nat Biotechnol 39, 128–130 (2021). https://doi.org/10.1038/s41587-021-00824-8
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41587-021-00824-8
This article is cited by
-
Signaling pathways and therapeutic interventions in gastric cancer
Signal Transduction and Targeted Therapy (2022)